Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v2.3.0.15
Consolidated Statements of Cash Flows (USD $)
6 Months Ended 336 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Net loss $ (3,039,377) $ (6,236,958) $ (51,511,323)
Depreciation and amortization 9,773 9,383 1,087,752
Amortization of deferred consulting fees     109,000
Loss on settlement of accrued interest and damages   68,703 1,037,951
Valuation allowance on note receivable   300,000  
Gain on sale of property and equipment     (13,065)
Gain on settlement of debt     (131,175)
Loss on settlement of accrued legal liabilities     142,245
Stock based compensation 448,062 1,298,168 4,497,801
Legal fees paid through the issuance of convertible debt     63,412
Fair market value of common shares donated to research institute     25,000
Loss on debt extinguishment   2,226,924 5,978,865
Fair market value of warrants issued in connection with accounts payable and debt     2,715,736
Fair market value of conditional warrants that subsequently were issued     106,201
Non cash interest expense 538,736 1,675,693 1,791,425
Liquidated damages     685,800
Fair market value of common stock, warrants and options issued for services 249,878 382,217 5,594,577
Change in fair value of derivative liabilities (1,521,502) (1,668,877) (6,282,598)
Termination fees paid through the issuance of notes payable 360,186   360,186
Patent license fees paid in stock     45,250
Amortization of debt discount and deferred financing costs 1,522,486 848,199 8,175,951
Impairment of intangible assets     1,313,253
Deferred compensation forgiven     217,223
Prepaid expenses and other assets 18,394 20,021 221,008
Accounts payable and other current liabilities 377,318 113,278 3,351,132
Due to related parties     1,268,383
Net cash used in operating activities (1,036,046) (963,249) (19,150,010)
Purchases of property and equipment (1,735) (875) (294,194)
Additions to patents and patents pending   (5,873) (407,235)
Proceeds from the sale of property and equipment     17,065
Cash of acquired company     10,728
Net cash used in investing activities (1,735) (6,748) (673,636)
Proceeds from the issuance of notes payable     2,350,000
Principal repayments of notes payable (5,000)   (381,500)
Net proceeds from the issuance of convertible notes payable 872,656 1,105,000 6,523,921
Proceeds from the issuance of common stock   283,600 10,753,535
Proceeds from collection of secured notes receivable 200,000   700,000
Professional fees related to registration statement     (76,731)
Net cash provided by financing activities 1,067,656 1,388,600 19,869,225
Net (decrease) increase in cash 29,875 418,603 45,579
Cash at beginning of period 15,704 67,950  
Cash at end of period 45,579 486,553 45,579
Interest     266,975
Income taxes     13,346
Derivative liabilities recorded in connection with embedded conversion feature of convertible notes and/or warrants   3,200,961  
Debt and accrued interest converted to common stock 1,472,611 385,508 7,824,434
Deferred financing costs recorded in connection with debt restructuring   80,054 80,054
Debt discount recorded in connection with beneficial conversion feature of convertible notes and related warrants 827,130 75,000 4,000,059
Issuance of convertible notes in settlement of accrued legal fees   35,469 35,469
Reclassification of accounts payable to notes payable     24,001
Reclassification of warrant derivative liability into equity 247,608   666,800
Additional convertible debt issued in debt restructuring     573,211
Stock option exercise by director for accrued expenses     95,000
Issuance of common stock, warrants and options in settlement of accrued expenses and due to related parties     1,003,273
Issuance of common stock in connection with acquisition of patent pending and with license agreements     118,000
Net assets of entities acquired in exchange for equity securities     1,597,867
Debt placement fees paid by issuance of warrants     856,845
Common stock issued for prepaid expenses     $ 161,537